Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study to Evaluate MEDI4736

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 23.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older.~* In the dose-escalation phase: histologically- or cytologically- confirmed advanced solid tumor that is refractory to standard therapy and for which no standard therapy exists.~* In the dose-expansion phase: histologically- or cytologically- confirmed advanced solid tumor where if an approved first-line therapy is available, participants must have failed, be intolerant to, be ineligible for, or have refused~* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1.~* Adequate organ and marrow function.~* Participants must have at least 1 measurable lesion.~* Available archived tumor tissue sample.~* Willingness to provide consent for biopsy sample (dose-expansion only)~Exclusion Criteria:~* Any prior Grade ≥ 3 immune-mediated adverse event (imAE) while receiving immunotherapy~* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody~* Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.~* Prior treatment with immunotherapy agents including, but not limited to, tumor necrosis factor receptor superfamily agonists or checkpoint inhibitors or natural killer (NK) cell inhibitors.~* Active or prior documented autoimmune disease within the past 2 years~* History of primary immunodeficiency~* History of organ transplant that requires use of immunosuppressives~* Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatment~* Other invasive malignancy within 2 years~* Women who are pregnant or lactating~* Uncontrolled intercurrent illness~* Known history of tuberculosis~* Known to be human immunodeficiency virus (HIV) positive~* Known to be Hepatitis B or C positive (except HCC participants)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Escalation Cohort (MEDI4736 0.1 mg/kg Q2W) (Type: EXPERIMENTAL): Participants will receive intravenous (IV) infusion of MEDI4736 (durvalumab) 0.1 mg/kg every 2 weeks (Q2W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Escalation Cohort (MEDI4736 0.3 mg/kg Q2W) (Type: EXPERIMENTAL): Participants will receive IV infusion of MEDI4736 0.3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Escalation Cohort (MEDI4736 1 mg/kg Q2W) (Type: EXPERIMENTAL): Participants will receive IV infusion of MEDI4736 1 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Escalation Cohort (MEDI4736 3 mg/kg Q2W) (Type: EXPERIMENTAL): Participants will receive IV infusion of MEDI4736 3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Escalation Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Escalation Cohort (MEDI4736 15 mg/kg Q3W) (Type: EXPERIMENTAL): Participants will receive IV infusion of MEDI4736 15 mg/kg every 3 weeks (Q3W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Exploration Durvalumab 20 mg/kg (Q4W) (Type: EXPERIMENTAL): Participants will receive IV infusion of MEDI4736 20 mg/kg every 4 weeks (Q4W) in the dose-exploration phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion Non-SCCHN Cohort HPV positive (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with non-SCCHN human papilloma virus positive (Non-SCCHN HPV+) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with non-small-cell lung cancer (NSCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with hepatocellular carcinoma (HCC Total) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with advance cutaneous melanoma (ACM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion UM Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with uveal melanoma (UM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with gastroesophageal cancer (GEC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with triple-negative breast cancer (TNBC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with pancreatic adenocarcinoma (PAC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion UC Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with urothelial carcinoma (UC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with glioblastoma multiforme (GBM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion OC Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with ovarian cancer (OC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion STS Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with soft- tissue sarcoma (STS) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with small-cell lung cancer (SCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with microsatellite instability (MSI)-high cancer will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
- Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W) (Type: EXPERIMENTAL): Participants with nasopharyngeal carcinoma (NPC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete